Allergan Inc (AGN.N)

AGN.N on New York Stock Exchange

164.38USD
21 Aug 2014
Price Change (% chg)

$1.25 (+0.77%)
Prev Close
$163.13
Open
$162.80
Day's High
$164.53
Day's Low
$162.58
Volume
164,334
Avg. Vol
374,112
52-wk High
$174.48
52-wk Low
$86.96

AGN.N

Chart for AGN.N

About

Allergan, Inc. is a multi-specialty health care Company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products. The Company’s segments include specialty pharmaceuticals, which produces a range of pharmaceutical products, including ophthalmic products for dry eye,... (more)

Overall

Beta: 0.75
Market Cap (Mil.): $48,479.59
Shares Outstanding (Mil.): 297.18
Dividend: 0.05
Yield (%): 0.12

Financials

  AGN.N Industry Sector
P/E (TTM): 37.37 33.58 34.30
EPS (TTM): 4.37 -- --
ROI: 14.59 18.87 18.12
ROE: 21.11 19.50 18.84
Search Stocks

U.S. court denies Allergan bid to speed insider trading suit

- A federal judge in California on Thursday denied a request by Allergan Inc to expedite its civil suit claiming that Valeant Pharmaceuticals International Inc and Pershing Square Capital Management engaged in insider trading ahead of their bid to buy Allergan.

21 Aug 2014

U.S. court denies Allergan bid to speed insider trading suit

- A federal judge in California on Thursday denied a request by Allergan Inc to expedite its civil suit claiming that Valeant Pharmaceuticals International Inc and Pershing Square Capital Management engaged in insider trading ahead of their bid to buy Allergan.

21 Aug 2014

UPDATE 1-U.S. court denies Allergan bid to speed insider trading suit

Aug 21 - A federal judge in California on Thursday denied a request by Allergan Inc to expedite its civil suit claiming that Valeant Pharmaceuticals International Inc and Pershing Square Capital Management engaged in insider trading ahead of their bid to buy Allergan.

21 Aug 2014

Federal court denies Allergan bid to speed insider trading suit

Aug 21 - A federal judge in California on Thursday denied a request by Allergan Inc to expedite its civil suit claiming that Valeant Pharmaceuticals International Inc and Pershing Square Capital Management engaged in insider trading ahead of their bid to buy Allergan.

21 Aug 2014

DEALTALK-RPT-As hunt for Allergan drags on, some Valeant owners have doubts

(Repeats for wider distribution (For more Reuters DEALTALKS, double click on )

20 Aug 2014

As hunt for Allergan drags on, some Valeant owners have doubts

NEW YORK/BOSTON - A few months ago, an innovative partnership between Valeant Pharmaceuticals and billionaire investor William Ackman to buy Botox maker Allergan Inc looked like a blueprint for success. Now some Valeant shareholders who backed the deal at its start are questioning whether it will become reality.

20 Aug 2014

Deals of the day- Mergers and acquisitions

Aug 19 - The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Tuesday:

19 Aug 2014

Allergan seeks deal with Salix to fend off Valeant: WSJ

- Botox maker Allergan Inc has approached Salix Pharmaceuticals Ltd and at least one other company about a potential takeover in a bid to avert the $53 billion hostile takeover from Valeant Pharmaceuticals International Inc, the Wall Street Journal said.

19 Aug 2014

Allergan seeks deal with Salix to fend off Valeant - WSJ

Aug 19 - Botox maker Allergan Inc has approached Salix Pharmaceuticals Ltd and at least one other company about a potential takeover in a bid to avert the $53 billion hostile takeover from Valeant Pharmaceuticals International Inc, the Wall Street Journal said.

19 Aug 2014

Allergan names company veteran Hindman CFO

Aug 18 - Botox-maker Allergan Inc, which is trying to fight off a hostile takeover bid from Valeant Pharmaceuticals Inc , said its chief financial officer, Jeff Edwards, was stepping down for family reasons and would be replaced immediately by 30-year company veteran Jim Hindman.

18 Aug 2014

Competitors

  Price Change
Astellas Pharma Inc (4503.T) ¥1,516 +0.50
Santen Pharmaceutical Co Ltd (4536.T) ¥6,230 -40.00
Lupin Limited (LUPN.NS) Rs1,236.60 -1.10
Nestle SA (NESN.VX) CHF70.35 +0.05
Johnson & Johnson (JNJ.N) $104.19 +0.98
Pfizer Inc. (PFE.N) $28.82 -0.07
Novartis AG (NOVN.VX) CHF81.30 +0.20
High Tech Pharm Co.,Ltd. (106190.KQ) ₩14,750.00 -250.00
Merck & Co., Inc. (MRK.N) $58.85 -0.63
Roche Holding Ltd. (ROG.VX) CHF264.90 -0.90

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00
Provider: MarketLine (a Datamonitor Company)
$175.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks